Does UnitedHealthcare Cover Wegovy? 2026 UHC Plan Matrix
Published:
·Last verified: May 21, 2026.·Next scheduled review: August 21, 2026The short answer: sometimes yes, often no — and the reason is two separate 2026 UHC programs that lead to opposite outcomes
Program P 1445-4 (most plans)
Weight loss = benefit exclusion. Wegovy still covered for cardiovascular risk reduction or MASH with PA.
Program P 1114-20 (opted-in plans)
Wegovy covered for weight loss with PA at BMI ≥30 (or ≥27 + comorbidity). 5-month initial auth, then ≥5% weight loss to renew.
Plan covers weight-loss drugs: Wegovy covered with PA. ~5-month first approval, then ≥5% weight loss to renew.
Plan excludes weight-loss drugs: Wegovy excluded for weight loss alone — but may still be covered for cardiovascular risk reduction or MASH. Each has its own PA path.
CA, NM, NY, or ND EHB plan: State requirements may force weight-loss medication coverage. North Dakota's bar is higher (BMI ≥40).
UHC Medicare Advantage / Part D: Weight loss alone excluded by federal law. CV risk reduction may be covered with PA. Medicare GLP-1 Bridge opens July 1, 2026 at $50/month.
UHC Medicaid / Community Plan: State by state. KFF reported 13 states covered GLP-1s for obesity under fee-for-service as of January 2026. Several states have since removed coverage.
Sources: UHC Programs 2026 P 1445-4 and P 1114-20, effective 5/1/2026 (uhcprovider.com); CMS Medicare GLP-1 Bridge (12/23/2025); FDA Wegovy CV indication (3/8/2024) and MASH indication (8/15/2025).
🩺 Check your UHC Wegovy coverage — free, no prescription required
The honest answer to “does my UHC plan cover Wegovy?” lives in your specific plan document. Ro’s free GLP-1 Insurance Coverage Checker asks for your insurance card info, contacts your plan, and emails a personalized report — coverage status, copay information, and any prior authorization requirements. Over 2 million people have used it.
Run my plan through Ro’s free coverage check →Affiliate link, disclosed. Coverage check does not guarantee approval. Ro Body membership and Wegovy medication are billed separately if you continue past the free report.
The UHC Wegovy Coverage Matrix
| Your UHC plan | Wegovy for weight loss alone | Wegovy for cardiovascular risk reduction | Wegovy injection for MASH (liver) |
|---|---|---|---|
| Commercial — plan did NOT elect weight-loss medication coverage | ❌ Non-formulary. Treated as a benefit exclusion under Program 2026 P 1445-4. | ✅ With PA. Age 45+, BMI ≥27, established CVD (prior MI, stroke, or symptomatic PAD), on standard cardiac background therapy. 12-month auth. | ✅ With PA. F2–F3 fibrosis on FibroScan, MRE, or biopsy within 12 months. Gastroenterologist or hepatologist required. 12-month auth. |
| Commercial — plan elected the optional Weight Loss/Appetite Suppression Medication Coverage program (P 1114-20) | ✅ With PA. BMI ≥30 or BMI ≥27 + comorbidity. Age ≥12 for injection, >16 for tablet. 5-month initial auth. Renewal needs ≥5% body-weight loss. | ✅ Same CV criteria. | ✅ Same MASH criteria (injection only). |
| Commercial — self-funded employer plan | Depends on employer benefit design. Self-funded employers can carve weight-loss medications in or out. | ✅ Generally with PA if the plan applies UHC's non-formulary criteria and the member meets them. | ✅ Generally with PA if the plan applies UHC's MASH criteria and the member meets them. |
| Individual ACA / Marketplace plan | Plan- and state-specific. Often excluded unless your plan is subject to a state weight-loss requirement. | ✅ With PA. | ✅ With PA. |
| UHC Medicare Advantage / Part D | ❌ Standard Part D coverage for weight loss alone is excluded under federal law. | ✅ Wegovy is coverable for the FDA-approved CV risk reduction indication on most Part D plans with PA — coverage and tier vary by plan. | ✅ Coverable for MASH with PA on plans that adopt the criteria; verify with your plan. |
| UHC Medicaid managed care / Community Plan | State-by-state. KFF reported 13 state Medicaid programs covered GLP-1s for obesity under fee-for-service as of January 2026. Several states have removed coverage since October 2025. | State-by-state. | State-by-state. |
Prior authorization (PA)
When your insurance has to approve a medication before it pays. Your prescriber sends paperwork; UHC reviews it; you wait for an answer.
Non-formulary
The drug isn’t on your plan’s regular covered list. It can still be covered through a special path (like the CV or MASH route), but only if you meet the rules.
Wegovy safety snapshot — read this before you book a visit
Boxed warning
Wegovy carries a boxed warning for thyroid C-cell tumors and is contraindicated in people with a personal or family history of medullary thyroid carcinoma or with multiple endocrine neoplasia syndrome type 2 (MEN2).
Additional warnings include pancreatitis, gallbladder disease, hypoglycemia, acute kidney injury, severe gastrointestinal reactions, hypersensitivity reactions, pulmonary aspiration during sedation, diabetic retinopathy complications (in patients with T2D), and possible reduced effectiveness of oral contraceptives. Wegovy is a prescription medication — a licensed clinician must decide whether it is appropriate for you. This is not complete safety information; read the full Wegovy prescribing information and discuss with your provider.
Why UHC says “yes” and “no” on the same drug
Two people with “UnitedHealthcare” on the same insurance card can get totally different Wegovy answers — because their plans are running on different UHC programs.
Program 2026 P 1445-4 — the non-formulary policy
Applies when a plan has NOT elected weight-loss medication coverage
UHC’s own language: “Medications for the purpose of weight loss are typically a benefit exclusion.” But — and most articles miss this — the same policy explicitly covers Wegovy for two non-weight-loss uses:
Cardiovascular risk reduction
Preventing a second major cardiovascular event (heart attack, stroke, or cardiovascular death) in adults with established CVD and obesity or overweight. 12-month auth.
MASH (metabolic dysfunction-associated steatohepatitis)
F2–F3 liver fibrosis confirmed on FibroScan, MRE, or biopsy within 12 months, prescribed by a gastroenterologist or hepatologist. Injection only. 12-month auth.
Program 2026 P 1114-20 — the optional weight-loss program
Applies when employer elected weight-loss coverage, or when state requirements apply
Covers Wegovy injection and Wegovy tablet with prior authorization at BMI ≥30 (or BMI ≥27 with a weight-related health condition). Initial authorization is 5 months. To renew, the patient needs to show ≥5% body-weight loss from baseline.
The optional program also runs automatically in California, New Mexico, New York, and North Dakota Essential Health Benefit (EHB) plans because those states have weight-loss medication requirements. North Dakota EHB is the strictest — it requires BMI ≥40 instead of ≥30.
Why this matters for what you do next
If your plan runs on P 1445-4
A stronger PA letter usually won’t fix a weight-loss denial. The rule isn’t “you didn’t prove medical necessity” — it’s “weight-loss medication isn’t a covered benefit.” Check whether you qualify under CV risk reduction or MASH, ask HR about adding the rider, or use an FDA-approved cash-pay path.
If your plan runs on P 1114-20
Your job is making sure the PA paperwork is airtight. Most denials on this program are documentation issues, not benefit issues. Missing BMI, missing comorbidity codes, missing lifestyle-modification notes — each one is fixable.
Can my employer exclude Wegovy even if UnitedHealthcare has a Wegovy policy?
Self-funded plans
Your employer pays the claims directly and uses UHC to administer the benefit. Employers choose their own benefit design — and many carve out anti-obesity medications. Escalation goes through HR, not UHC. No PA in the world overrides an employer exclusion.
Fully insured plans
UHC carries the financial risk and sells the policy to the employer. These still have employer-selected options, including whether to include the optional weight-loss program. State mandates may apply on top.
The right question to ask UHC
Call UHC and ask whether the optional Weight Loss/Appetite Suppression Medication Coverage program applies to your plan — that’s the program name to use. A formulary tier display, an OptumRx search result, or a friend’s UHC outcome don’t override the plan document.
Does OptumRx cover Wegovy if UnitedHealthcare says no?
The OptumRx trap
You log in, see “Wegovy — Tier 3” in OptumRx, and assume it’s covered. It might not be.
The OptumRx tier tells you what category Wegovy would fall in if it’s covered. It doesn’t tell you whether your specific plan covers it. The plan-level benefit decision lives in your benefit document, not in the OptumRx interface.
Two questions to ask UHC/OptumRx to clear the confusion
1. "Is Wegovy covered under my pharmacy benefit at my specific plan, and at what tier?"
2. "Is the weight-loss medication benefit included on my plan, or is that excluded? If excluded, does my plan still allow Wegovy under the cardiovascular risk reduction or MASH non-formulary criteria?"
If the answer to question 2 is “excluded,” the answer to question 1 doesn’t really matter — you’re going to be denied at the pharmacy. Switch strategies (CV/MASH pathway, HR escalation, or cash-pay) instead of appealing a decision that was never going to be approved through standard PA.
How to check your UHC plan in 60 seconds
4-step DIY check (no call needed)
- 1Go to myuhc.com and sign in (the UHC app works too).
- 2Open Pharmacy → Prescription Drug List or Medication Search.
- 3Type Wegovy.
- 4Read what shows up — then use the key below.
"Covered" or "Covered with PA"
Wegovy has a covered path on your plan. Confirm which path before assuming weight loss is covered.
"Not covered" or "Excluded"
Your plan didn't elect weight-loss coverage. Non-formulary rules apply. You may still have a path via CV risk reduction or MASH.
"Pending" or blank
Call the number on the back of your card and use the script below.
The exact words to use when you call UHC
Don’t ask “do you cover Wegovy” — that’s how you get a technically-true, practically-useless answer. Ask this:
“I want to verify Wegovy coverage on my specific plan. Three questions: (1) Is Wegovy on my pharmacy formulary, and at what tier? (2) Does my plan include the optional Weight Loss/Appetite Suppression Medication Coverage program, or is weight-loss medication excluded? (3) If weight loss is excluded, does my plan still allow Wegovy under the cardiovascular risk reduction or MASH non-formulary criteria?”
Write down the rep’s name and the call reference number. If they say “covered with PA,” ask them to email or mail the PA criteria. If they say “excluded,” get that confirmation in writing.
Or skip the call entirely
Ro’s checker asks for your insurance card info, contacts your insurance plan, and emails you a personalized report — coverage results, any copay or cost estimates, and any prior authorization requirements. No prescription is needed. Over 2 million people have used it.
Check my coverage through Ro’s free GLP-1 Insurance Coverage Checker →UHC’s prior authorization rules for Wegovy (the exact 2026 criteria)
| Requirement | Weight loss (P 1114-20) | CV risk reduction (P 1445-4) | MASH (P 1445-4) |
|---|---|---|---|
| Minimum age | ≥12 (injection); >16 (tablet) | 45+ | Adults |
| BMI | ≥30 OR ≥27 + comorbidity (hypertension, dyslipidemia, T2D, sleep apnea, etc.) | ≥27 | Not required for MASH initial |
| Required diagnoses / evidence | Documented diet, activity, behavioral support, or program | Prior MI, prior ischemic/hemorrhagic stroke, or symptomatic PAD (with specific evidence) | Fibrosis stage F2 or F3 on VCTE (FibroScan), MRE, or liver biopsy within 12 months |
| Background therapy | — | Varies by CV history: cholesterol-lowering therapy, ACE-I/ARB/ARNI, antiplatelet; beta blocker for post-MI unless contraindicated. | — |
| Excluded if | — | Diabetes diagnosis or HgA1c >6.5%; NYHA Class IV heart failure | Cirrhosis; concurrent Rezdiffra for the same indication |
| Specialist required | No | Prescriber addresses background-therapy adequacy | Gastroenterologist or hepatologist |
| Initial auth length | 5 months | 12 months | 12 months |
| Renewal criteria | ≥5% body-weight loss + continued lifestyle modification | Per 2/2026 policy update: no new BMI re-check at renewal; no diabetes diagnosis or HgA1c >6.5%; no NYHA Class IV heart failure | Positive clinical response; no progression to cirrhosis |
What changed in February 2026
The BMI requirement was removed from CVD reauthorization. You still need BMI ≥27 to start. But renewals no longer re-check BMI. Weight changes after approval don’t put your renewal at risk on the CV pathway.
Wegovy tablets were added alongside Wegovy injection in the CV pathway, with criteria now differentiated by formulation.
If your prescriber is preparing a CV-pathway PA using an older policy version, push for the May 2026 effective version.
Important formulation difference: Wegovy injection vs Wegovy tablet
Wegovy injection
Indicated for adults AND pediatric patients aged 12+ for weight management, for cardiovascular risk reduction, and for MASH.
Wegovy tablet
Indicated for adults ONLY for weight management and cardiovascular risk reduction. Not indicated for pediatric weight management or for MASH.
If you’re a teen patient, a MASH patient, or your prescriber is choosing between formulations, this difference can change what your insurance can approve.
The honest thing we owe you about the 5-month authorization
UHC’s initial weight-loss authorization is only 5 months. Zepbound (also in Program P 1114-20) gets 6 months. Five months sounds fine until you realize you have to lose ≥5% of your body weight by then, then resubmit reauthorization paperwork to keep coverage.
If your plan covers both Wegovy and Zepbound and your prescriber is open to either, that 1-month gap is worth a conversation. But — Wegovy is FDA-approved for cardiovascular risk reduction and noncirrhotic MASH with F2–F3 fibrosis. Zepbound is not. If either of those pathways applies to you, the 12-month authorization on those routes more than wipes out the weight-loss gap.
UHC Wegovy PA Documentation Checklist
Print this and hand it to your prescriber’s medical assistant. Most fixable denials are missing items from this list.
Weight-loss pathway
- Patient name and UHC member ID
- Date of birth
- Current height
- Current weight + date measured
- BMI (calculated) + date measured
- Baseline weight before Wegovy
- Weight-related comorbidity if BMI is 27–29.9 (with ICD-10 code — e.g., hypertension, dyslipidemia, OSA)
- Documented lifestyle modification (diet, activity, behavioral support, prior weight-loss attempts with dates)
CV risk reduction pathway
- Date of birth confirming age 45+
- BMI ≥27 documentation
- Established CVD: prior MI / ischemic or hemorrhagic stroke / symptomatic PAD with specific evidence
- Background therapy: cholesterol-lowering med, ACE-I/ARB/ARNI, antiplatelet (and beta blocker for post-MI unless contraindicated)
- Most recent HgA1c (must not exceed 6.5%)
- No diabetes diagnosis
- No NYHA Class IV heart failure
MASH pathway
- Fibrosis stage F2 or F3 confirmed by VCTE (FibroScan), MRE, or liver biopsy within the past 12 months
- No cirrhosis
- Gastroenterologist or hepatologist named on the prescription/PA
- No concurrent Rezdiffra for the same indication
- PA submission date
- PA tracking / reference number
- Denial letter (if applicable) with exact reason text
- UHC call reference numbers and rep names
🩺 Have someone else build the PA packet
A common reason UHC denies Wegovy isn’t a benefit exclusion — it’s incomplete paperwork. Ro says its insurance concierge works with insurance providers to determine GLP-1 coverage and, for eligible Ro Body members, can handle coverage paperwork on your behalf.
Check whether Ro can help with your Wegovy coverage paperwork →Affiliate link, disclosed. Ro Body membership ($39 first month, then $149/month or as low as $74/month with annual prepay) is billed separately from Wegovy medication cost. Treatment requires clinician approval.
What Wegovy actually costs with UnitedHealthcare
| Your situation | What you may pay each month | Source / notes |
|---|---|---|
| UHC covers Wegovy + commercial insurance + Wegovy Savings Offer | As little as $25/month, max savings $100/month | wegovy.com Savings Offer; defines 'month' as one box of four pens or one bottle of 30 tablets |
| UHC covers Wegovy, no savings card (or government insurance) | Plan tier copay; commonly Tier 4 specialty at $25–$300+ | UHC formulary tiers; ask UHC for your specific copay |
| UHC excludes Wegovy — NovoCare self-pay (pen, new patient intro) | $199/month for first two monthly fills of 0.25 mg or 0.5 mg pens through June 30, 2026 | wegovy.com / novocare.com |
| UHC excludes Wegovy — NovoCare self-pay (pen, ongoing) | $349/month for 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, or 2.4 mg pens | novocare.com |
| UHC excludes Wegovy — NovoCare self-pay (Wegovy HD 7.2 mg) | $399/month | novocare.com |
| UHC excludes Wegovy — NovoCare self-pay (Wegovy tablet) | $149/month for 1.5 mg ongoing; $149/month for 4 mg through Aug 31, 2026 then $199/month; $299/month for 9 mg and 25 mg | wegovy.com |
| UHC excludes Wegovy — Ro cash-pay (telehealth) | Same cash-pay prices as NovoCare; Ro Body membership separate ($39 first month, $149/month monthly, or as low as $74/month annual prepay) | ro.co/weight-loss/pricing |
| Retail at a pharmacy with no coverage or discount | Often quoted above $1,300 | Verify at your pharmacy; the useful question is which path you actually qualify for |
Government beneficiaries are excluded from the commercial savings offer. If you're on Medicare, Medicaid, or Tricare, your real options are the CV pathway, the Medicare GLP-1 Bridge (starting July 1, 2026), state Medicaid coverage where it exists, or NovoCare/Ro self-pay.
Even covered, you may pay full price during your deductible. A Tier 4 specialty drug on a high-deductible plan can cost full retail in January and $25 in March. Ask UHC: "What will I pay before vs. after my deductible?"
Self-pay through NovoCare and Ro is the same medication. NovoCare is direct-from-Novo-Nordisk; Ro adds telehealth provider visits, the GLP-1 Insurance Coverage Checker, coaching, and the option to try insurance first.
Why your UHC Wegovy denial happened — and what to do next
| What the denial says | What it likely means | Best next step |
|---|---|---|
| "Prior authorization required — not approved" | Paperwork incomplete or didn't meet criteria | Fix the gap and resubmit; usually faster than a formal appeal |
| "BMI not documented" or "BMI does not meet threshold" | Missing height/weight/BMI in the chart, or BMI <30 without a documented comorbidity | Add measurement date, weight, height, BMI, comorbidity diagnosis codes |
| "Lifestyle modification not documented" | The prescriber's note didn't mention diet, activity, behavioral support | Add a single paragraph in the chart note describing the program |
| "Not on formulary" / "Non-formulary" | Default UHC policy applies; plan didn't elect weight-loss program | Ask about formulary exception OR check CV/MASH pathway |
| "Benefit exclusion — anti-obesity medications" | Employer carved weight-loss meds out of the plan | Medical-necessity appeal usually won't override this. Try CV/MASH pathway, HR escalation, or cash-pay |
| "Not medically necessary" | Criteria not clearly mapped to your case | Re-submit with explicit criteria-by-criteria match to UHC's policy |
| "Reauthorization denied" | Didn't document ≥5% body-weight loss | Submit baseline weight + current weight + percentage |
| "Diagnosis mismatch" | Diagnosis code doesn't match the requested use | Update ICD-10 codes (E66.01 obesity, or CV/MASH codes for non-weight-loss path) |
The appeal window
Under federal rules for group health plans, claimants generally have at least 180 days after an adverse benefit determination to file an appeal. Read your specific denial letter for the controlling deadline.
A corrected PA is faster than a formal appeal. If the denial was paperwork-related, your prescriber can resubmit with the gap fixed. That clock is days, not months.
A benefit exclusion usually cannot be fixed by adding more medical paperwork. Switch strategies instead of writing the same letter twice.
Two mistakes real UHC members make
Mistake #1: Trusting the OptumRx tier display
Members see “Wegovy — Tier 3” in OptumRx and assume their plan covers it. The tier shows what category Wegovy falls in if it’s covered. The employer can still exclude it. Always check both: the formulary listing AND the plan’s benefit exclusions.
Mistake #2: Appealing a benefit exclusion as if it were a paperwork denial
Members write strong medical-necessity letters and still lose. If the plan document excludes weight-loss meds, no medical letter overrides the contract. The right move is a CV or MASH indication PA, an HR conversation, or a cash-pay route.
🩺 If your denial was a true benefit exclusion, don't fight the wrong battle
Insurance appeals can take weeks or months. If your UHC denial was a benefit exclusion (not a paperwork denial) and you’re committed to starting, Ro offers FDA-approved Wegovy at the same cash-pay prices as NovoCare, LillyDirect, and TrumpRx — and Ro’s insurance concierge can keep working on coverage in the background if your situation changes.
Compare FDA-approved Wegovy options through Ro →Affiliate link, disclosed. Ro Body membership billed separately. Treatment requires clinician approval.
Does UHC Medicare Advantage cover Wegovy?
Path 1 — Cardiovascular risk reduction (the Medicare path right now)
On March 8, 2024, the FDA expanded Wegovy’s approval to include reducing the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight. The Part D exclusion targets drugs used for weight loss. CV risk reduction is a different FDA-approved use — and opened a Part D coverage path.
A Medicare patient who meets all of the following may be eligible:
Coverage and copay vary by plan. Meeting this list doesn’t guarantee approval, but it’s the right conversation to have with your cardiologist or PCP.
Path 2 — Medicare GLP-1 Bridge (July 1, 2026 – December 31, 2027)
On December 23, 2025, CMS announced the Medicare GLP-1 Bridge. Eligible Medicare Part D beneficiaries will have access to certain GLP-1 medications — including all formulations of Wegovy — for $50 per month. The Bridge covers Wegovy injection and tablets when used to reduce excess body weight and maintain weight reduction. A provider must submit a prior authorization request and prescription for an eligible use under the demonstration.
CMS caveats:
- ·Beneficiaries in private fee-for-service plans, 1876 cost contract plans, 1833 health care prepayment plans, PACE organizations, fallback plans, and religious fraternal benefit plans aren't directly eligible unless also enrolled in a standalone Part D plan.
- ·Dually-eligible beneficiaries (Medicare + Medicaid) need an eligible Part D plan type AND must meet the PA criteria.
If you’re a UHC Medicare member who doesn’t qualify under the CV pathway today, the Medicare GLP-1 Bridge is the path to watch. Final PA criteria and operational details will be published by CMS as the program launches.
🧭 Not sure which path is yours? Take the 60-second quiz
Medicare members, Medicaid members, and people in employer plans without coverage all have different next steps. Our GLP-1 Path matching quiz asks five questions and returns a personalized action plan.
Take the free 60-second GLP-1 Path quiz →UHC Medicaid and Wegovy: it depends on your state
What to do:
- 1Find your state Medicaid drug list (sometimes called a Preferred Drug List or PDL).
- 2Look up Wegovy specifically. Note whether it's preferred, non-preferred, requires PA, or is excluded.
- 3Check whether step therapy applies — when your state requires trying a cheaper drug first before approving Wegovy.
- 4Call your UHC Community Plan member services and confirm.
The four states with weight-loss medication requirements
| State | What’s required | Notes |
|---|---|---|
| California | Plans subject to the California weight-loss medication requirement may have coverage under P 1114-20. | Manufacturer savings card terms may have California-specific limitations if an FDA-approved therapeutic equivalent exists (none currently for Wegovy). |
| New Mexico | Plans subject to the New Mexico requirement may have coverage under P 1114-20. | — |
| New York | Plans subject to the New York requirement may have coverage under P 1114-20. | — |
| North Dakota | Applies only to Fully Insured EHB (Small Group and Individual) plans. BMI requirement is ≥40 instead of ≥30. Pediatric criteria are stricter: BMI >120% of the 95th percentile. | The only state in the program with a tighter BMI threshold. |
Living in one of these states doesn’t automatically mean your plan is covered by the requirement. Self-funded plans, federal plans, and certain other categories may be outside the state’s reach. If you live in CA, NM, NY, or have a ND EHB plan and your UHC plan still shows Wegovy as excluded, ask UHC whether the state requirement applies to your specific plan type before assuming it should be covered.
What to do if your UHC plan won’t cover Wegovy at all
Try the CV or MASH pathway first
Before paying anything out of pocket, ask your prescriber: "Do I qualify under the cardiovascular risk reduction or MASH indications?" If you have prior heart attack, stroke, or peripheral artery disease, or fibrosis stage F2–F3 on FibroScan/MRE/biopsy, you may already have a covered path.
Don't pay cash-pay if you qualify for coverage.
Ask your employer if they'll add the rider
Novo Nordisk publishes a sample employer coverage request letter you can give to HR. Larger self-funded employers are increasingly adding the weight-loss rider because GLP-1 demand is high. Worth a 15-minute conversation with HR — especially close to your plan's renewal.
Plan for open enrollment
If your employer offers multiple plan options and you're stuck with one that excludes weight-loss meds, check the others. Some UHC plan tiers include the optional weight-loss program even when others don't. Open enrollment happens once a year — set a calendar reminder.
Compare the three real cash-pay routes
NovoCare Pharmacy (direct from Novo Nordisk)
- Pen intro: $199/month for first two fills of 0.25 mg or 0.5 mg through June 30, 2026
- Pen ongoing: $349/month (0.25–2.4 mg)
- Wegovy HD 7.2 mg: $399/month
- Tablet 1.5 mg: $149/month ongoing
- Tablet 4 mg: $149/month through Aug 31, 2026 then $199/month
- Tablet 9 mg / 25 mg: $299/month
No insurance involved. Still needs a prescription.
Ro (telehealth with FDA-approved Wegovy)
- Same cash-pay prices as NovoCare, LillyDirect, and TrumpRx
- Ro Body: $39 first month, then $149/month or as low as $74/month annual prepay
- Membership and medication billed separately
- Includes provider visits, GLP-1 Insurance Coverage Checker, insurance concierge, coaching
Sesame Care (cash-pay marketplace)
- Provider-choice marketplace; pricing varies by clinician
- Multiple FDA-approved GLP-1s available
- Best fit if you want to pick a specific provider
Who should NOT use cash-pay (we'll tell you to leave)
If you have all of the following:
Stop. Don’t pay cash yet.
Ask your cardiologist or PCP about the UHC cardiovascular risk reduction pathway specifically — that pathway is covered under UHC’s default non-formulary policy on most commercial plans, gets a 12-month authorization when criteria are met, and is dramatically cheaper than 12 months of cash-pay.
Wegovy pill vs. Wegovy pen: are they covered differently by UHC?
Three questions to ask UHC if you’re choosing between pill and pen
- 1Are both formulations on my plan's formulary?
- 2Do both require prior authorization, or just one?
- 3Is the tier the same for both?
Some plans tier the pill and pen differently, which can mean meaningfully different copays. And if you’re a teen or a MASH patient, only Wegovy injection is FDA-indicated for you regardless of what your plan formulary shows.
How we built this page — and what we verified
Last verified: May 21, 2026. Next scheduled review: August 21, 2026.
What we actually verified (May 21, 2026)
- ✓UnitedHealthcare Pharmacy Clinical Pharmacy Programs 2026 P 1445-4 (Wegovy Non-Formulary — Cardiovascular Risk Reduction and MASH Only), effective 5/1/2026. P&T approval dates: 4/2024, 5/2025, 11/2025, 2/2026. Source: uhcprovider.com.
- ✓UnitedHealthcare Pharmacy Clinical Pharmacy Programs 2026 P 1114-20 (Plans with Weight Loss/Appetite Suppression Medication Coverage), effective 5/1/2026. Most recent P&T approval: 2/2026. Source: uhcprovider.com.
- ✓NovoCare Pharmacy self-pay pricing and Wegovy Savings Offer terms — wegovy.com, novocare.com (verified May 2026).
- ✓CMS Medicare GLP-1 Bridge announcement and $50/month structure, December 23, 2025 — cms.gov.
- ✓FDA Wegovy prescribing information. CV indication FDA-approved March 8, 2024. MASH indication FDA-approved August 15, 2025.
- ✓KFF Medicare and Medicaid GLP-1 coverage briefs (January 2026 data on Medicaid; analysis of Wegovy CV indication and Medicare coverage).
- ✓Ro Wegovy insurance, pricing, and coverage-checker pages — ro.co (verified May 2026).
What we did NOT do
- ·We did not assume every UHC plan covers Wegovy. UHC's two published policies say otherwise depending on plan type.
- ·We did not assume an OptumRx formulary tier overrides plan exclusions. The plan document controls.
- ·We did not treat a PA denial and a benefit exclusion as the same problem. They have different responses.
- ·We did not fabricate a "medically reviewed by Dr. ___" credential. No clinician was asked to review this page in writing.
- ·We did not recommend compounded GLP-1s on this page. Wegovy is a brand-name FDA-approved medication.
- ·We did not invent denial-rate or appeal-success statistics.
Frequently Asked Questions
Does UnitedHealthcare cover Wegovy for weight loss?
UnitedHealthcare's 2026 non-formulary policy (Program 2026 P 1445-4) states that medications for the purpose of weight loss are typically a benefit exclusion — meaning most commercial UHC plans that have not elected weight-loss medication coverage do not cover Wegovy for weight loss alone. Coverage is available if your employer elected UHC's optional Weight Loss/Appetite Suppression Medication Coverage program (P 1114-20), or if your plan is subject to applicable weight-loss medication requirements in California, New Mexico, New York, or North Dakota EHB plans.
Does UHC cover Wegovy without diabetes?
Yes, when the plan covers weight-loss medications. The PA requires BMI ≥30 or BMI ≥27 with a weight-related comorbidity. For the cardiovascular risk reduction pathway, you actually cannot have a diabetes diagnosis or HgA1c >6.5% and still qualify under UHC's specific non-formulary criteria.
Does UHC Medicare cover Wegovy?
Not for weight loss alone. Federal law excludes drugs prescribed for weight loss from Medicare Part D coverage. UHC Medicare Advantage and standalone Part D plans may cover Wegovy for cardiovascular risk reduction (FDA-approved March 2024) on most plans with PA. Beginning July 1, 2026, eligible Medicare Part D beneficiaries may also access Wegovy through the CMS Medicare GLP-1 Bridge demonstration at $50 per month.
How much is Wegovy with UnitedHealthcare?
With commercial UHC coverage and the Wegovy Savings Offer, eligible patients may pay as little as $25 per month, with maximum savings capped at $100/month. Without coverage or for government beneficiaries, NovoCare Pharmacy self-pay is $199/month for the first two monthly fills of 0.25 mg or 0.5 mg pens for new patients through June 30, 2026, then $349/month for ongoing pens; $399/month for Wegovy HD 7.2 mg; $149/month for Wegovy 1.5 mg tablets and for 4 mg tablets through August 31, 2026; and $299/month for 9 mg and 25 mg tablets.
Does OptumRx cover Wegovy?
OptumRx administers UnitedHealthcare's pharmacy benefit. Whether Wegovy is paid at the pharmacy depends on your specific UHC plan's coverage and exclusions. If your plan covers Wegovy, OptumRx processes the prior authorization and claim. If your plan excludes weight-loss medications, OptumRx will deny the claim at the pharmacy regardless of how Wegovy is tiered in the formulary search.
Can my employer exclude Wegovy even if UHC has a Wegovy policy?
Yes. Self-funded employer plans can carve weight-loss medications in or out of the benefit. State mandates, federal rules, UHC clinical criteria, and your member-specific benefit document can all still affect the answer. Your plan document is the controlling answer, not another UHC member's experience.
What is the UHC initial authorization length for Wegovy?
Under Program P 1114-20 (the optional weight-loss program), UHC's initial authorization for Wegovy injection or tablet is 5 months. Reauthorization requires documented ≥5% body-weight loss from baseline plus continued lifestyle modification, and is issued for 12 months. Under Program P 1445-4 for cardiovascular risk reduction or MASH, initial authorization is 12 months.
Why did UHC deny my Wegovy prior authorization?
Common UHC Wegovy denial reasons include: your plan excludes weight-loss medications entirely; BMI documentation is missing or doesn't meet the threshold; lifestyle modification documentation is missing from the prescriber's note; or the PA was submitted with insufficient comorbidity documentation when BMI is 27–29. UHC's denial letter will specify the exact reason. Paperwork denials are the fixable ones — resubmit with the missing documentation. Benefit-exclusion denials usually require a different strategy.
What's the difference between UHC's two Wegovy policies?
Program 2026 P 1445-4 is the non-formulary policy used when a plan has not elected weight-loss medication coverage — Wegovy is non-formulary, weight loss is treated as a benefit exclusion, and only the cardiovascular risk reduction and MASH indications are covered with PA. Program 2026 P 1114-20 is the optional Weight Loss/Appetite Suppression Medication Coverage program — applied when employers elect it or when state requirements apply (CA, NM, NY, ND EHB). Under P 1114-20, Wegovy is covered for weight loss with PA at BMI ≥30 or ≥27 with a comorbidity.
Can I use the Wegovy Savings Card with UnitedHealthcare?
If you have commercial UnitedHealthcare insurance (not Medicare Advantage, Medicare Part D, Medicaid, or Tricare), the Wegovy Savings Offer may apply. Government beneficiaries are excluded under the savings offer terms. The offer combines with commercial coverage to reduce out-of-pocket cost to as little as $25 per month, with maximum savings of $100/month.
Does UHC require step therapy for Wegovy?
UHC's published 2026 weight-loss program doesn't list a universal step-therapy requirement in the core Wegovy criteria, but plan-specific step therapy rules, state mandates, and member-specific benefit terms can still apply. Always verify whether your specific plan requires you to try a cheaper anti-obesity medication first.
What if my UHC plan covers Wegovy but my deductible isn't met yet?
You may pay close to the full negotiated price until your annual deductible is met. After the deductible, your standard tier copay or coinsurance kicks in. On a high-deductible health plan, this can be the difference between $25/month after deductible and $1,000+ before it. Ask UHC: "What will I pay before vs. after my deductible?" before filling.
How long does UnitedHealthcare's Wegovy PA take?
UHC says prior authorization timing varies by plan and request type — a review can take as little as a few days or as long as a month, and urgent requests may be rushed. Ask UHC/OptumRx for the exact expected timeline on your plan.
Sources
- 1.UnitedHealthcare Pharmacy Clinical Pharmacy Programs 2026 P 1445-4 — Wegovy® (semaglutide) injection, Wegovy® (semaglutide) tablets — Cardiovascular Risk Reduction and MASH Only. Effective 5/1/2026. uhcprovider.com.
- 2.UnitedHealthcare Pharmacy Clinical Pharmacy Programs 2026 P 1114-20 — Plans with Weight Loss/Appetite Suppression Medication Coverage. Effective 5/1/2026. uhcprovider.com.
- 3.CMS Medicare GLP-1 Bridge. Announced December 23, 2025; effective July 1, 2026 – December 31, 2027. cms.gov.
- 4.FDA Wegovy prescribing information. Cardiovascular indication FDA-approved March 8, 2024. MASH indication FDA-approved August 15, 2025.
- 5.Novo Nordisk. Wegovy Cost & Coverage Information — wegovy.com.
- 6.NovoCare Pharmacy self-pay pricing — novocare.com/wegovy.
- 7.KFF. "A New Use for Wegovy Opens the Door to Medicare Coverage for Millions of People with Obesity." kff.org.
- 8.KFF. "Medicaid Coverage of and Spending on GLP-1s." kff.org (January 2026 update).
- 9.Ro weight loss insurance, pricing, and coverage-checker pages — ro.co.
- 10.U.S. Department of Labor. Benefit Claims Procedure Regulation FAQs (180-day appeal window for group health plans). dol.gov.
Still not sure which path is yours?
Coverage pathways, prior-authorization rules, Medicare timing, and cash-pay options can blur together fast. Our GLP-1 Path matching quiz takes about 60 seconds. You answer five questions about your plan, indication, and situation, and we return a personalized action plan with the next concrete step for your case.
Ro and Sesame links are affiliate links, disclosed above. The /find-my-path/ quiz is free with no email required.
This guide is informational only and is not medical, legal, or insurance advice. Coverage policies and pricing change frequently. Verify the current policy with UnitedHealthcare, OptumRx, and your prescriber before acting on any of this information. The RX Index is a pricing intelligence and comparison resource for GLP-1 telehealth providers. We may earn a commission when readers sign up for a provider through links on this page; this does not change our editorial process.
Published:
· Last verified: May 21, 2026. · Next scheduled review: August 21, 2026.Affiliate disclosure: The RX Index earns a commission when you sign up with some of the providers mentioned on this page. It does not affect what you pay, and it never determines our rankings or which providers we cover. Read the full disclosure.